In a study carried out in mice at the University of Chicago, researchers found that lasofoxifene outperformed fulvestrant, the current gold-standard drug, in reducing or preventing primary tumor growth.
Following chemo, survivors suffer with memory dysfunction. The first large-scale study underway on cognitive behavioral therapy.
JAMA articles by UT Health San Antonio surgeon provide guidance for MDs, families
Detection innovation could enhance drug development and cancer research
ESMO Breast Cancer 2021 Virtual Congress, 5-8 May
Bentham Science has recently launched the new volume of the book, Frontiers in Clinical Drug…
Clinical data reveals new link between body weight and breast cancer survival
BOSTON – Concerns about fertility often influence how young women with breast cancer approach treatment…
Primary care practitioners often over-estimate the likelihood of a patient having a medical condition based on reported symptoms and laboratory test results. Such overestimations can lead to over-diagnosis and overtreatment, according to a recent study conducted by researchers at the University of Maryland School of Medicine (UMSOM) published in JAMA Internal Medicine.
Lugano, Switzerland, 28 April 2021 – The 2021 ESMO Breast Cancer Congress will be held…
Individuals with metastatic breast cancer could soon have access to personalized, supplemental supportive care through their smart speaker, thanks to new research at Penn State.
Cells from women with African American ancestry responded more strongly to the compound
A new study arm opens, expanding patients’ potential to qualify for the trial when they may not have other options; the available treatments target tumor defects with drugs that show efficacy evidence; testing labs continue to identify trial candidates
Dartmouth researchers achieve better long-term control of drug-resistant breast cancer growth in mice by switching between estrogen and anti-estrogen therapies. A new clinical trial will inform which patients may benefit from this strategy
Women at high risk of breast cancer face cost-associated barriers to care even when they have health insurance, a new study has found. The findings suggest the need for more transparency in pricing of health care and policies to eliminate financial obstacles to catching cancer early.
Two studies led by Baylor College of Medicine shed new light on the unanswered question…
Research indicates the rate of cancer recurrence or survival may be no different in older women diagnosed with early breast cancer whether they were treated or untreated.
Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with a high fatality…
Most African American women described successfully navigating the challenges of a breast cancer diagnosis with their partners, finds a new analysis from the Brown School at Washington University in St. Louis.
New research led by the Garvan Institute of Medical Research has revealed how breast cancer…
Detecting and analyzing breast cancer goes beyond the initial discovery of the cancer itself. If…
According to the American Cancer Society, a noninvasive breast cancer called ductal carcinoma in situ (DCIS) accounts for approximately one of every four new breast cancer cases in the United States. If left untreated, DCIS has the potential to evolve into invasive cancer, so many patients choose to have breast-conserving surgery or mastectomy after a diagnosis.
New research from the UVA Cancer Center could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials.
New Breast Imaging Technology at Hackensack Meridian Mountainside Medical Center Delivers Mammograms in 3D and Enhances Delivery of Care
Hackensack Meridian Mountainside Medical Center is advancing the fight against breast cancer with the purchase and installation of MAMMOMAT Revelation, an innovative mammography system designed to overcome barriers to breast cancer detection and ProFound Artificial Intelligence for digital breast tomosynthesis, a deep-learning artificial intelligence software that rapidly and accurate identifies potential malignant lesions.
Scientists train deep learning algorithms to classify breast lesions from ultrasound images in a large multi-center study
Researchers at the University of California, San Francisco, have discovered that aggressive, triple-negative breast cancers (TNBCs) can evade treatment by reorganizing and softening the collagen matrix that surrounds the cancer cells. The study, which will be published April 2 in the Journal of Experimental Medicine (JEM), shows that the softer matrix activates a signaling pathway that promotes the cancer cells’ survival, and suggests that targeting this pathway could enhance the effectiveness of chemo- and radiotherapy in TNBC patients.
Researchers in Italy have identified a pair of microRNA molecules that help maintain a population of cancerous stem cells that drive the growth of breast cancers and initiate tumor relapse after treatment. The study, which will be published April 2 in the Journal of Cell Biology (JCB), reveals that targeting these microRNAs makes cancer stem cells more susceptible to some chemotherapies and could potentially improve the prognosis of patients with aggressive forms of breast cancer.
Despite a strong rebound in mammography volume, missed mammograms remain an issue
In order to develop more effective drugs against a range of cancers, researchers have been…
American Association for Cancer Research honors distinguished USC Norris Comprehensive Cancer Center scientist
In addition, the classification enables the prediction of the benefits of a cell cycle inhibitor
In one of the largest research projects of its kind, a new study published in JAMA Network Open looks at nearly 900,000 individuals and close to 2 million mammograms to come up with a new way to detect the most breast cancer cases with the fewest exams.
A team of researchers at Dartmouth’s Geisel School of Medicine, led by Glyn Elwyn, MD,…
Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than…
Live virtual conference drew global oncology professionals to share best practices and highlight advances and issues in cancer care
The Oncotarget article provides evidence that antitumor activity and prolonged stable disease are achieved with Z-endoxifen despite prior tamoxifen therapy.
People who are physically active on a regular basis recover better after surgery for colorectal…
New sequencing approach finds triple-negative breast cancers continue accumulating genetic changes during tumor growth
Novel technique for single-cell single-molecule DNA sequencing enables faster, deeper study of chromosome evolution with possible clinical and research implications
The Health Equity Breakthrough Team includes clinical cancer specialists and experts in the social science components of community health
A gene not previously linked to cancer has been shown to play a key role…
This Oncotarget study had significantly lower mutation rates in ASXL1 and SETBP1, and a higher rate of muTET2/wtASXL1
The Oncotarget data shed new light on the biochemical mechanisms behind ibuprofen’s action on alternative spliced RAC1B and may support its use in personalized approaches to CRC therapy or chemoprevention regimens.
Dr. Glenn J. Hanna from CCR/NCI in Bethesda, MD as well as The Dana-Farber Cancer Institute in Boston Massachusetts said, “Merkel cell carcinoma (MCC) is a relatively rare cancer, with roughly 400 cases per 100,000 persons each year in the United States”
Breast cancer is the most common type of tumour found in women. 69,000 new cases…
Commonly used medications for type 2 diabetes and obesity called glucagon like peptide-1 receptor agonists (GLP-1 RAs), are not associated with an increased risk of breast cancer, despite previous studies that suggested a possible link, according to a study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
Findings relieve concerns arising from clinical trials of liraglutide
The Louisiana State University School of Veterinary Medicine, or LSU SVM, has received an $11…
AJR findings suggest possible role of contrast-enhanced mammography for staging in women with breast augmentation and contraindication or limited access to MRI
The present Oncotarget work shed light on a brief mechanistic framework of PTs aggressive nature and present potential biomarkers to differentiate overlapping FELs that would be of practical utility in augmenting existing diagnosis and disease management
While the drug tamoxifen reduces the risk of developing breast cancer and prevents recurrence, the…